Trump's HHS Secretary Pick Raised Drug Prices as Executive

Опубликовано 14 ноября 2017, 18:26
Despite Donald Trump saying his nominee for HHS secretary, Alex Azar will “be a star for … lower drug prices!" the record of the former top executive for Eli Lilly suggests a different story. Lilly is one of three drug corporations targeted by a class-action lawsuit that accuses the company, then under Azar’s watch, of exploiting the drug pricing system to ensure higher profit for insulin. In recent years, Azar has also defended pricing practices, and argued against approaches to reduce costs to consumers such as allowing the U.S. government to negotiate drug prices and imported medicine from overseas.

This video was produced by YT Wochit News using
Случайные видео